AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.90
+1.90%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$29.31
From 52W high−16.81%
Volume1.21M
Market cap$1.42B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$29.31
From 52W high
−16.81%
Volume
1.21M
Market cap
$1.42B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
P/E (TTM)
—
RSI (14)
46.0
MomentumView details →
1D Return
+1.90%
YTD Return
+44.34%
SummaryUpdated Jun 1, 2026
ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania. The company went public in January 2024 and focuses on developing targeted cancer therapies, particularly for non-small-cell lung cancer and other solid tumors. ArriVent operates in the highly specialized field of oncology drug development, with its lead asset being an advanced-stage cancer treatment currently in Phase 3 clinical trials.
Similar companies
Latest newsMore news →